Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101

ABSTRACT MICs were determined for an investigational ketolide, CEM-101, and azithromycin, telithromycin, doxycycline, levofloxacin, clindamycin, and linezolid against 36 Mycoplasma pneumoniae, 5 Mycoplasma genitalium, 13 Mycoplasma hominis, 15 Mycoplasma fermentans, and 20 Ureaplasma isolates. All isolates, including two macrolide-resistant M. pneumoniae isolates, were inhibited by CEM-101 at ≤0.5 μg/ml, making CEM-101 the most potent compound tested.

Download Full-text

Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00849-08 ◽

2008 ◽

Vol 52 (10) ◽

pp. 3776-3778 ◽

Cited By ~ 8

Author(s):

Ken B. Waites ◽

Donna M. Crabb ◽

Lynn B. Duffy

Keyword(s):

Mycoplasma Pneumoniae ◽

Antimicrobial Agents ◽

Mycoplasma Hominis ◽

Mycoplasma Genitalium ◽

The Other ◽

Vitro Activity ◽

Clinical Isolates ◽

In Vitro Activity ◽

Mycoplasma Fermentans

ABSTRACT The in vitro susceptibilities of 151 unique clinical isolates of Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma fermentans, Mycoplasma genitalium, and Ureaplasma species to DC-159a, an investigational fluoroquinolone, in comparison with those to other agents were determined. Macrolides were the most active agents against M. pneumoniae and M. genitalium, whereas clindamycin was most active against M. hominis. DC-159a MICs were ≤0.5 μg/ml for all Mycoplasma species and ≤4 μg/ml for ureaplasmas. DC-159a was the most active fluoroquinolone tested against M. pneumoniae and M. fermentans, and it was second to moxifloxacin against the other species. It was bactericidal against 10 M. pneumoniae isolates and demonstrated killing of ≥99.9% of the inoculum at 24 h for 2 isolates. The excellent in vitro activity of DC-159a demonstrates its potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.

Download Full-text

In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00698-20 ◽

2020 ◽

Vol 64 (8) ◽

Author(s):

Ken B. Waites ◽

Donna M. Crabb ◽

Li Xiao ◽

Lynn B. Duffy ◽

Sixto M. Leal

Keyword(s):

Mycoplasma Pneumoniae ◽

Antimicrobial Agents ◽

Susceptibility Testing ◽

Ureaplasma Urealyticum ◽

Mycoplasma Hominis ◽

Mycoplasma Genitalium ◽

Content Type ◽

Ureaplasma Parvum

ABSTRACT We performed in vitro susceptibility testing for eravacycline in comparison to 4 other antimicrobials against 10 Mycoplasma genitalium, 40 Mycoplasma hominis, 44 Mycoplasma pneumoniae, 20 Ureaplasma parvum, and 20 Ureaplasma urealyticum isolates. All eravacycline MICs were ≤0.25 μg/ml, except that for one isolate of M. genitalium, for which the MIC was 2 μg/ml. Eravacycline was markedly more potent than tetracycline, azithromycin, moxifloxacin, and clindamycin against all isolates tested, which included 37 macrolide, tetracycline, and/or fluoroquinolone-resistant organisms.

Download Full-text

In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.47.1.39-42.2003 ◽

2003 ◽

Vol 47 (1) ◽

pp. 39-42 ◽

Cited By ~ 45

Author(s):

Ken B. Waites ◽

Donna M. Crabb ◽

Lynn B. Duffy

Keyword(s):

Mycoplasma Pneumoniae ◽

Mycoplasma Hominis ◽

Mycoplasma Fermentans

ABSTRACT The in vitro susceptibilities of 103 Mycoplasma pneumoniae isolates, 14 Mycoplasma hominis isolates, 12 Mycoplasma fermentans isolates, and 24 Ureaplasma species to ABT-773, an investigational ketolide, and seven other agents were determined. For M. pneumoniae, the ABT-773 MIC at which 90% of isolates are inhibited (MIC90; ≤0.001 μg/ml) was comparable to those of azithromycin, clarithromycin, and erythromycin and at least 128-fold lower than those of levofloxacin, gatifloxacin, moxifloxacin, and doxycycline. For M. fermentans, the ABT-773 MIC90 (≤0.008 μg/ml) was 2- to 128-fold lower than those of all other agents tested. For M. hominis, the ABT-773 MIC90 (0.031 μg/ml) was equivalent to that of moxifloxacin, 2-fold lower than those of gatifloxacin and clindamycin, and 16-fold lower than that of levofloxacin. ABT-773 was equally active against doxycycline-susceptible and doxycycline-resistant organisms. The ABT-773 MICs (0.016 μg/ml) for Ureaplasma species were the lowest of those of any drug tested. The MIC90 was 4- to 64-fold lower than those of clarithromycin, azithromycin, and erythromycin and ≥16-fold lower than those of all three fluoroquinolones. Minimal bactericidal concentrations determined for a subgroup of organisms were ≤0.063 μg/ml for M. pneumoniae and 0.25 μg/ml for M. fermentans, but they were several dilutions higher for M. hominis and Ureaplasma spp. ABT-773 has great potential for further study for the treatment of infections due to mycoplasmas and ureaplasmas.

Download Full-text

Comparative In Vitro Susceptibilities and Bactericidal Activities of Investigational Fluoroquinolone ABT-492 and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.47.12.3973-3975.2003 ◽

2003 ◽

Vol 47 (12) ◽

pp. 3973-3975 ◽

Cited By ~ 32

Author(s):

Ken B. Waites ◽

Donna M. Crabb ◽

Lynn B. Duffy

Keyword(s):

Mycoplasma Pneumoniae ◽

Antimicrobial Agents ◽

Mycoplasma Hominis ◽

Mycoplasma Fermentans ◽

Bactericidal Activities

ABSTRACT We determined in vitro susceptibilities for ABT-492 and other antimicrobials against Mycoplasma pneumoniae, Mycoplasma fermentans, Mycoplasma hominis, and Ureaplasma species. ABT-492 MICs were ≤1 μg/ml, and the agent was bactericidal against selected isolates of M. pneumoniae and M. hominis. ABT-492 has potential for treatment of infections due to these microorganisms.

Download Full-text

Antimycoplasmal Activity of Hydroxytyrosol

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.48.12.4892-4894.2004 ◽

2004 ◽

Vol 48 (12) ◽

pp. 4892-4894 ◽

Cited By ~ 30

Author(s):

Pio Maria Furneri ◽

Anna Piperno ◽

Antonella Sajia ◽

Giuseppe Bisignano

Keyword(s):

Mycoplasma Pneumoniae ◽

Mycoplasma Hominis ◽

Mycoplasma Fermentans

ABSTRACT The aim of this study was to investigate the in vitro antimycoplasmal activity of hydroxytyrosol. Twenty strains of Mycoplasma hominis, three strains of Mycoplasma fermentans, and one strain of Mycoplasma pneumoniae were used. For M. pneumoniae, M. hominis, and M. fermentans, the MICs were 0.5, 0.03 (for 90% of the strains tested), and 0.25 μg/ml, respectively.

Download Full-text

Comparative In Vitro Activities of Investigational Peptide Deformylase Inhibitor NVP LBM-415 and Other Agents against Human Mycoplasmas and Ureaplasmas

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.49.6.2541-2542.2005 ◽

2005 ◽

Vol 49 (6) ◽

pp. 2541-2542 ◽

Cited By ~ 15

Author(s):

Ken B. Waites ◽

Nipun B. Reddy ◽

Donna M. Crabb ◽

Lynn B. Duffy

Keyword(s):

Mycoplasma Pneumoniae ◽

Mycoplasma Hominis ◽

Peptide Deformylase ◽

Mycoplasma Fermentans ◽

Modest Activity

ABSTRACT Peptide deformylase inhibitor LBM-415 and seven other drugs were tested against Mycoplasma pneumoniae (100 isolates), Mycoplasma hominis (20 isolates), Mycoplasma fermentans (10 isolates), and Ureaplasma species (50 isolates). LBM-415 was active against M. pneumoniae (MICs, ≤0.008 μg/ml). It showed no activity against M. hominis and M. fermentans and modest activity against Ureaplasma spp.

Download Full-text

In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.47.1.161-165.2003 ◽

2003 ◽

Vol 47 (1) ◽

pp. 161-165 ◽

Cited By ~ 53

Author(s):

Ken B. Waites ◽

Donna M. Crabb ◽

Xue Bing ◽

Lynn B. Duffy

Keyword(s):

Mycoplasma Pneumoniae ◽

Antimicrobial Agents ◽

Active Drug ◽

Mycoplasma Hominis ◽

The Other ◽

Mycoplasma Fermentans ◽

Bactericidal Activities ◽

Time Kill

ABSTRACT The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63 Mycoplasma pneumoniae, 45 Mycoplasma hominis, 15 Mycoplasma fermentans, and 68 Ureaplasma sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at ≤1 μg/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC90s; ≤0.008 μg/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin for M. pneumoniae. For M. hominis, the garenoxacin MIC90 (≤0.008 μg/ml) was 4-fold less than those of clindamycin and moxifloxacin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin. All 15 M. fermentans isolates were inhibited by garenoxacin at concentrations ≤0.008 μg/ml, making it the most active drug tested against this organism. For Ureaplasma spp., the garenoxacin MIC90 (0.25 μg/ml) was equivalent to those of moxifloxacin and doxycycline, 4-fold less than those of levofloxacin and sparfloxacin, 8-fold less than that of azithromycin, and 32-fold less than that of ciprofloxacin. Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against M. pneumoniae and M. hominis by measurement of minimal bactericidal activities and by time-kill studies. Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.

Download Full-text

In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.01064-17 ◽

2017 ◽

Vol 61 (10) ◽

Cited By ~ 6

Author(s):

Ken B. Waites ◽

Donna M. Crabb ◽

Li Xiao ◽

Lynn B. Duffy

Keyword(s):

Topoisomerase Ii ◽

Antimicrobial Agents ◽

Ureaplasma Urealyticum ◽

Mycoplasma Hominis ◽

Mycoplasma Genitalium ◽

Content Type ◽

Topoisomerase Ii Inhibitor ◽

Ureaplasma Parvum ◽

Type Strains

ABSTRACTGepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains and clinical isolates ofMycoplasma pneumoniae,Mycoplasma hominis,Mycoplasma genitalium,Ureaplasma parvum, andUreaplasma urealyticumin comparison to levofloxacin, moxifloxacin, azithromycin or clindamycin, and tetracycline. Gepotidacin MIC90s (μg/ml) were 0.125 (M. pneumoniae), 0.032 (M. genitalium), 2 (M. hominis), and 8 (Ureaplasmaspecies). Gepotidacin activity was not affected by resistance to fluoroquinolones, tetracyclines, or macrolides in the strains tested. Gepotidacin merits further study for treating infections caused by these organisms.

Download Full-text